Literature DB >> 19067727

Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma.

Frederik A Verburg1, Uwe Mäder, Markus Luster, Christoph Reiners.   

Abstract

OBJECTIVE: To study the relationship between primary tumour size and the risk of advanced disease features (multifocal or locally invasive disease, lymph-node or distant metastases) in differentiated thyroid carcinoma (DTC).
DESIGN: A retrospective chart review study. PATIENTS: The study sample comprised 935 papillary (PTC) and 291 follicular thyroid carcinoma (FTC) patients treated in our hospital from 1978 to 2007. MEASUREMENTS: Kaplan-Meier analyses and log-rank tests were performed to calculate tumour size-adjusted cumulative risk of advanced disease features.
RESULTS: Accounting for primary tumour diameter, there were no significant differences in cumulative risks of multifocal carcinoma (P = 0.12) or distant metastases (P = 0.49) between PTC and FTC. PTC showed higher cumulative risks of local invasion (P < 0.0001) or lymph-node metastases (P < 0.0001). The cumulative risk of tumour multifocality increased 5%/cm of primary tumour diameter. The cumulative risk of local invasion or lymph-node metastases in PTC and of distant metastases in DTC increased exponentially at a threshold tumour diameter of 10 mm. In FTC, lymph-node metastases are associated almost exclusively with primary tumours showing extrathyroidal growth.
CONCLUSIONS: Starting with a 1 cm primary tumour diameter, increasing tumour size is associated with an exponentially increasing risk of local invasion or lymph-node or distant metastases of DTC. The current classification of carcinomas < 2 cm as T1 is therefore questionable.

Entities:  

Mesh:

Year:  2008        PMID: 19067727     DOI: 10.1111/j.1365-2265.2008.03482.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].

Authors:  M Stratmann; C Sekulla; H Dralle; M Brauckhoff
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

Review 2.  Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach.

Authors:  Marguerite T Parisi; Hedieh Khalatbari; Sanjay R Parikh; Adina Alazraki
Journal:  Pediatr Radiol       Date:  2019-10-16

3.  Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment.

Authors:  Alexis Vrachimis; Kurt Werner Schmid; Heribert Jürgens; Otmar Schober; Matthias Weckesser; Burkhard Riemann
Journal:  Dtsch Arztebl Int       Date:  2013-12-13       Impact factor: 5.594

Review 4.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

5.  Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.

Authors:  Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-13       Impact factor: 9.236

6.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

7.  Risk factors associated with intrathyroid extension of thyroid microcarcinomas.

Authors:  Nikola Slijepcevic; Vladan Zivaljevic; Aleksandar Diklic; Milan Jovanovic; Branislav Oluic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2018-05-17       Impact factor: 3.445

8.  Ectopic thyroid papillary carcinoma of nasopharynx associated with adenoid hypertrophy: an unusual presentation.

Authors:  Linli Tian; Yufei Jiao; Ming Liu; Minghua Li; Hongchao Yao
Journal:  Head Face Med       Date:  2014-09-20       Impact factor: 2.151

Review 9.  Pediatric papillary thyroid cancer: current management challenges.

Authors:  Frederik A Verburg; Hanneke M Van Santen; Markus Luster
Journal:  Onco Targets Ther       Date:  2016-12-28       Impact factor: 4.147

Review 10.  Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade.

Authors:  Frederik A Verburg; Glenn Flux; Luca Giovanella; Douglas van Nostrand; Kristoff Muylle; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.